Affiliate disclosure: Some links in this article are affiliate links. We may earn a commission at no additional cost to you.

Medical disclaimer: This article is for informational purposes only and is not medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before starting any supplement, particularly if you take medications or have a thyroid condition, autoimmune disorder, or are pregnant.

TL;DR

• Ashwagandha (Withania somnifera) is an Ayurvedic adaptogenic herb with human RCT evidence on stress biomarkers, including serum cortisol.
• The Chandrasekhar et al. 2012 randomized, double-blind, placebo-controlled trial (64 adults, KSM-66 at 600 mg/day for 60 days) found that the ashwagandha group had significantly lower cortisol levels and self-reported stress scores compared to placebo — cortisol reduction was approximately 28% from baseline.
• A 2014 systematic review by Pratte and colleagues covering five human trials found consistent directional results for ashwagandha’s anxiolytic effects, while noting that methodological quality varied considerably across studies.
• KSM-66 and Sensoril are the two standardized extracts with the most documented trial use; they differ in plant part used and withanolide concentration.
• Typical studied doses: 300–600 mg/day of KSM-66, usually split across two doses. Higher doses have not consistently shown proportionally stronger effects in available data.
• Ashwagandha interacts with thyroid medications and sedatives. It is not appropriate during pregnancy, and the long-term evidence base for safety beyond six months is limited.

What is ashwagandha, and why does it appear alongside Japanese wellness?

Ashwagandha is not Japanese. It is a root from the Solanaceae family, cultivated primarily in India, the Himalayas, and North Africa, and central to Ayurvedic practice for centuries. The connection to Japanese wellness is market-driven rather than cultural: Japan has seen rapid growth in adaptogenic supplement imports over the past decade, and ashwagandha now appears widely on shelves alongside native Japanese wellness products — and on international sites under “Japanese adaptogen” search queries, partly because Western consumers associate Japan with high-quality, research-oriented supplement curation.

For context on how ashwagandha compares to plants that actually originate in Japan, see our separate piece: Ashwagandha vs. Japanese Adaptogens: Reishi, Ashitaba, and Eucommia.

The practical question for someone purchasing from Japan-adjacent wellness channels remains the same as from any other source: what does the human evidence actually show, and for which extract and dose?

The Chandrasekhar 2012 trial: what it measured and what it found

The most cited single ashwagandha trial on stress biomarkers is Chandrasekhar K et al., published in the Indian Journal of Psychological Medicine (2012;34(3):255–262). This was a randomized, double-blind, placebo-controlled trial conducted over 60 days in 64 adults with a self-reported history of chronic stress.

Participants received either KSM-66 ashwagandha root extract at 300 mg twice daily (600 mg total per day) or placebo. Primary outcomes included:

• Perceived Stress Scale (PSS) scores — a validated self-report instrument
• Serum cortisol — measured at baseline and day 60
• Secondary measures of anxiety (GHQ-28 subscale), depression subscale, and general wellbeing

Results at 60 days showed statistically significant differences between groups. PSS scores decreased by approximately 44% from baseline in the ashwagandha group versus about 5.5% in the placebo group. Serum cortisol levels fell by approximately 28% in the ashwagandha group versus roughly 8% in placebo. Wellbeing measure improvements were directionally consistent.

Three calibrations before drawing firm conclusions from this trial.

First, a sample of 64 adults is small by clinical standards. The findings are directionally consistent with other ashwagandha research, but replication in larger samples would substantially strengthen confidence.

Second, serum cortisol is one proxy for stress biology, not a comprehensive measurement. Cortisol fluctuates meaningfully with measurement timing, sleep, food intake, and other confounders. The 28% reduction is notable but should be read alongside the PSS findings rather than as a standalone biomarker claim.

Third, participants self-selected as experiencing chronic stress. Results in populations without that baseline burden may differ.

Pratte et al. 2014: the systematic review landscape

Pratte MA and colleagues published a systematic review in the Journal of Alternative and Complementary Medicine (2014;20(12):901–908) covering five published human trials on ashwagandha and anxiety or stress outcomes. Trial designs ranged from open-label to randomized controlled, with varying dose regimens and outcome instruments.

The overall finding was that across trial designs, ashwagandha appeared associated with reduced anxiety and stress, with safety profiles broadly acceptable at studied doses. The review also noted a consistent limitation: methodological heterogeneity across studies made pooling effect sizes problematic. No two trials used identical outcome measures, extract preparations, or dose protocols.

What systematic reviews with this kind of heterogeneity establish is directional consistency — findings moving in the same direction across independent research groups — rather than a precise effect size applicable to any individual situation.

The sleep quality connection

One dimension that has received increasing research attention is ashwagandha’s association with sleep quality. A 2019 randomized, double-blind trial published in Cureus (Langade et al., 2019;11(9):e5797) enrolled 60 adults and found that KSM-66 at 300 mg twice daily was associated with significantly improved self-reported sleep quality, reduced sleep onset latency, and better morning alertness over 10 weeks compared to placebo.

This is mechanistically consistent with the cortisol findings: chronically elevated cortisol is associated with fragmented sleep architecture, particularly disrupted slow-wave sleep. Whether ashwagandha’s sleep quality signal is downstream of its cortisol association, or represents a separate pathway, has not been established in the available trials.

For the broader context of sleep, cortisol, and supplementation in a Japanese longevity framing — including the trial evidence for L-theanine and magnesium glycinate — see our Japan sleeping habits and longevity evidence article.

KSM-66 versus Sensoril: the two standardized extracts

Purchasing an ashwagandha supplement typically means choosing between two frequently cited standardized extracts:

KSM-66 is produced by Ixoreal Biomed and derived from the ashwagandha root only. It contains approximately 5% withanolides (the bioactive compounds associated with adaptogenic effects) by weight. Most of the larger published RCTs — including Chandrasekhar 2012 and Langade 2019 — used KSM-66 at 600 mg/day.

Sensoril is produced by Natreon and uses both root and leaf. It typically specifies higher withanolide concentrations (around 10%) and is often tested at lower absolute doses. Earlier dose-finding research (Auddy B et al., Journal of the American Nutraceutical Association, 2008;11(1):50–56) examined Sensoril at 125, 250, and 500 mg/day and found dose-dependent reductions in self-reported stress scores and cortisol, with significant differences from placebo at all three doses.

For a buyer: KSM-66 has the larger published evidence base at the 600 mg/day dose level, while Sensoril has dose-finding data that may be relevant for lower-dose options. Products on Amazon and iHerb carry both; the extract form will be specified on the label if the product uses a named standardized extract rather than commodity root powder.

Dose and timing

The most studied dose in human trials is 600 mg/day of KSM-66, split into two 300 mg doses with meals. This protocol appears in Chandrasekhar 2012, Langade 2019, and several other KSM-66 trials. There is no strong trial evidence that higher doses produce meaningfully better outcomes; the dose-response relationship above 600 mg/day is not well characterized in published human data.

Many commercial products offer 300 mg or 500 mg per capsule. If your daily intake is 300 mg (one capsule), you are at the lower end of what has been studied — the trial effect sizes, already modest, may not apply at half the dose.

On timing: the 300 mg morning / 300 mg evening split used in the Chandrasekhar trial is the most studied pattern. Taking the full dose in the evening is also commonly recommended on product packaging, though there is limited comparative data on split versus single-dose timing for the specific outcomes studied.

Side effects and who should not take ashwagandha

At studied doses over 8–12 weeks, ashwagandha has shown a broadly acceptable tolerability profile in published trials. Most commonly reported adverse events were mild: digestive discomfort, occasional drowsiness, and loose stools at higher doses.

Where the evidence does not yet provide coverage:

• Long-term safety beyond 6 months in any population
• Pregnancy — ashwagandha is traditionally contraindicated and there is no clinical safety data to recommend its use during pregnancy
• Autoimmune conditions — as an immunomodulatory plant, it may theoretically affect immune activity; people with lupus, rheumatoid arthritis, Hashimoto’s thyroiditis, or other autoimmune conditions should consult a physician before use
• Thyroid medications — ashwagandha has thyroid-stimulating associations in animal studies and isolated case reports; anyone on levothyroxine or thyroid suppression therapy should consult their prescribing physician before starting
• Sedatives, anxiolytics, or CNS depressants — potential additive sedation

If you are on any prescription medication, the relevant question is not “is ashwagandha safe” in the abstract, but “is ashwagandha safe with what I am already taking” — which requires the clinical context a physician has and a supplement article does not.

How to find a product worth trying

When comparing ashwagandha products, the most reliable filters are: does the label specify KSM-66 or Sensoril as the extract form (rather than generic “ashwagandha root powder”)? Is the withanolide percentage stated? Is there a certificate of analysis available from the brand’s website or on request?

Search KSM-66 ashwagandha 600mg on Amazon — look for products that name the KSM-66 extract and specify 300 mg or 600 mg per serving.

Search Sensoril ashwagandha capsules on Amazon — Sensoril-specific products will name the extract on the label and typically specify a withanolide percentage.

Both extract forms are also available on iHerb with user review data that can supplement manufacturer-side documentation.

What the evidence actually supports — and what it does not

The honest position on ashwagandha and cortisol in 2026:

• The Chandrasekhar 2012 trial is a methodologically adequate small RCT showing cortisol and stress reductions associated with KSM-66 at 600 mg/day over 60 days. It is the best single trial on record for this compound and these outcomes.
• The Pratte 2014 systematic review adds directional consistency: across five studies with varying designs, ashwagandha appeared associated with reduced anxiety and stress scores.
• The Langade 2019 trial extends this signal to sleep quality outcomes, which is mechanistically consistent with a reduced cortisol burden over time.
• None of these trials establishes that ashwagandha modifies disease outcomes. The evidence supports a modest cortisol and perceived-stress signal in small adult samples with self-reported stress burden. This does not translate into any clinical treatment claim.

For readers building a broader longevity supplement context — including compounds with overlapping cellular-health angles — see our NMN supplements and Japan: hype vs evidence and NMN vs NR comparison for a reference point on how supplement evidence looks when held to similar calibration standards.

If stress is significantly affecting daily function, sleep, or relationships, the clinical path — physician assessment, licensed therapist, evidence-based behavioral interventions — has a substantially larger evidence base than any adaptogenic supplement. Ashwagandha sits in the category of a calibrated-evidence bet at a modest dose, not a clinical solution. And as with all supplements in this category: if you start, set a defined trial period, track one or two simple personal metrics, and reassess rather than continuing indefinitely on marketing momentum.

---

Sources: Chandrasekhar K, Kapoor J, Anishetty S. “A Prospective, Randomized Double-Blind, Placebo-Controlled Study of Safety and Efficacy of a High-Concentration Full-Spectrum Extract of Ashwagandha Root in Reducing Stress and Anxiety in Adults.” Indian J Psychol Med. 2012;34(3):255–262. Pratte MA, Nanavati KB, Young V, Morley CP. “An Alternative Treatment for Anxiety: A Systematic Review of Human Trial Results Reported for the Ayurvedic Herb Ashwagandha (Withania somnifera).” J Altern Complement Med. 2014;20(12):901–908. Langade D, Kanchi S, Salve J, Debnath K, Ambegaokar D. “Efficacy and Safety of Ashwagandha (Withania somnifera) Root Extract in Insomnia and Anxiety: A Double-blind, Randomized, Placebo-controlled Study.” Cureus. 2019;11(9):e5797. Auddy B, Hazra J, Mitra A, Abedon B, Ghosal S. “A Standardized Withania Somnifera Extract Significantly Reduces Stress-Related Parameters in Chronically Stressed Humans.” J Am Nutraceutical Assoc. 2008;11(1):50–56.